Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Grand Pharmaceutical Group Limited ( (HK:0512) ) just unveiled an update.
Grand Pharmaceutical Group Limited plans to overhaul its constitutional documents by adopting a new set of bye-laws to replace its existing ones, subject to shareholder approval at the annual general meeting on 5 June 2026. The changes are designed to align the company with Hong Kong’s expanded paperless listing regime, electronic dissemination of corporate communications, the new treasury shares framework, and the move toward an uncertificated securities market, with additional housekeeping revisions to keep its governance in step with updated listing requirements.
A circular detailing the proposed amendments and convening the AGM will be sent to shareholders in due course, ensuring investors are informed ahead of the vote on the special resolution. The initiative underscores the company’s effort to modernise its corporate governance framework and operational infrastructure in line with regulatory developments, which may enhance administrative efficiency and regulatory compliance for stakeholders.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company incorporated in Bermuda, engaged in the healthcare industry and traded under stock code 00512. The company is governed by a board comprising four executive directors and four independent non-executive directors, reflecting a typical governance structure for a sizable listed healthcare issuer.
Average Trading Volume: 5,600,779
Technical Sentiment Signal: Buy
Current Market Cap: HK$22.5B
See more data about 0512 stock on TipRanks’ Stock Analysis page.